GRP and prostate cancer: As a result, 40–200 nm monodisperse nanoparticles with neutral zeta potential showed high entrapment of DTX and GRP motif on the surface and enhanced specific binding of their hybrid carriers to prostate cancer cells, but not to GRPR-free cells (Figure 12).